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ABSTRACT
Objectives: The objectives were to evaluate the safety, reactogenicity, and allele-specific
immunogenicity of the blood-stage malaria vaccine FMP1/AS02A in adults exposed to seasonal
malaria and the impact of natural infection on vaccine-induced antibody levels.
Design: We conducted a randomized, double-blind, controlled phase I clinical trial.
Setting: Bandiagara, Mali, West Africa, is a rural town with intense seasonal transmission of
Plasmodium falciparum malaria.
Participants: Forty healthy, malaria-experienced Malian adults aged 18–55 y were enrolled.
Interventions: The FMP1/AS02A malaria vaccine is a 42-kDa recombinant protein based on
the carboxy-terminal end of merozoite surface protein-1 (MSP-142) from the 3D7 clone of P.
falciparum, adjuvanted with AS02A. The control vaccine was a killed rabies virus vaccine
(Imovax). Participants were randomized to receive either FMP1/AS02A or rabies vaccine at 0, 1,
and 2 mo and were followed for 1 y.
Outcome Measures: Solicited and unsolicited adverse events and allele-specific antibody
responses to recombinant MSP-142 and its subunits derived from P. falciparum strains
homologous and heterologous to the 3D7 vaccine strain were measured.
Results: Transient local pain and swelling were more common in the malaria vaccine group
than in the control group (11/20 versus 3/20 and 10/20 versus 6/20, respectively). MSP-142
antibody levels rose during the malaria transmission season in the control group, but were
significantly higher in malaria vaccine recipients after the second immunization and remained
higher after the third immunization relative both to baseline and to the control group.
Immunization with the malaria vaccine was followed by significant increases in antibodies
recognizing three diverse MSP-142 alleles and their subunits.
Conclusions: FMP1/AS02A was well tolerated and highly immunogenic in adults exposed to
intense seasonal malaria transmission and elicited immune responses to genetically diverse
parasite clones. Anti-MSP-142 antibody levels followed a seasonal pattern that was significantly
augmented and prolonged by the malaria vaccine.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
An effective vaccine directed against the blood stages of
Plasmodium falciparum malaria would prevent severe disease
and death in African children and other at-risk populations.
Merozoite surface protein-1 (MSP-1) is a 195-kDa antigen
found on the surface of P. falciparum merozoites. It is essential
for merozoite invasion of erythrocytes, after ﬁrst being
processed to yield a carboxy-terminal 42 kDa fragment
(MSP-142) that is further cleaved into the MSP-133 and MSP-
119 fragments, as reviewed in [1]. MSP-1 has promise as a
blood-stage malaria vaccine [2], but genetic polymorphism of
the antigen [3,4] could limit vaccine efﬁcacy if the protection
conferred is allele speciﬁc.
Falciparum malaria protein 1 (FMP1) consists of recombi-
nant MSP-142 from the 3D7 clone of P. falciparum produced in
and puriﬁed from Escherichia coli [5]. Reconstituted with the
AS02A adjuvant, an oil-in-water formulation containing the
immunostimulants monophosphoryl lipid A and QS21, it
constitutes the FMP1/AS02A malaria vaccine. At the time of
this study, this vaccine had been evaluated in two clinical
trials evaluating a total of 60 malaria-naı ¨ve North American
adults ([6] and D. G. Heppner, unpublished data), and in a
further trial in 20 Kenyan adults exposed to intense year-
round malaria transmission [7]. In these trials FMP1/AS02A
was well tolerated and no safety concerns were identiﬁed.
The vaccine was highly immunogenic in malaria-naı ¨ve
volunteers, inducing antibodies that recognized parasites by
indirect ﬂuorescent antibody (IFA), were reactive against
recombinant fragments of MSP-142 (including subdomains)
by enzyme-linked immunosorbent assay (ELISA), and meas-
urably inhibited parasite growth. Kenyan adults exposed to
intense year-round malaria transmission had high and
variable background levels of anti-MSP-142 antibodies, and
differences in antibody levels between malaria vaccine and
control groups were not signiﬁcant at any post-immunization
timepoint; however, signiﬁcant differences in antibody levels
were measured when a longitudinal model was applied [7].
The safety, immunogenicity, and efﬁcacy of malaria
vaccines may be affected by the intensity and pattern of
local malaria transmission, which determines levels of pre-
existing natural immunity and potential natural ‘‘boosting’’
of the immune response to vaccines, and may affect the
prevalence of different allelic parasite types. Western Kenya
and Bandiagara, Mali, represent two sites with very different
transmission patterns, both representative of other malaria-
endemic areas where a vaccine would eventually be offered.
We assessed the FMP1/AS02A malaria vaccine compared to
rabies vaccine in adults living in Bandiagara, Mali, where
malaria is highly seasonal and naturally acquired immunity is
lower than in western Kenya. To investigate the speciﬁcity of
vaccine-induced antibody responses, antibodies to diverse
MSP-142 alleles and subunits were measured.
METHODS
Study Setting
The Bandiagara Malaria Project research clinic is adjacent to
the district hospital in Bandiagara, a rural town of 13,634
inhabitants in the Dogon Country in northeast Mali. It is
relatively dry, with a mean annual rainfall of 600 mm in 2002.
Anopheles gambiae is the principal malaria vector. Malaria
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Editorial Commentary
Background: In sub-Saharan Africa the burden of death and disease
from malaria is particularly severe. Most affected are young children
under the age of five, in whom natural immunity against the malaria
parasite has not yet developed. There are not yet any approved vaccines
that would reduce this burden, although many research groups are
currently developing potential vaccines. One such candidate vaccine is
FMP1/AS02A. This vaccine is designed to trigger an immune response
against a protein (merozoite surface protein-1, or MSP-1) found on the
surface of the infectious, blood-stage form of the malaria parasite. Early-
stage clinical trials have already been performed in healthy people in the
United States, who were not exposed to clinical malaria, and in Kenyan
adults who are exposed to malaria throughout the year. These studies
did not identify any safety concerns regarding the candidate vaccine,
which meant that it could progress further in clinical testing. As part of
this next stage, a group of researchers wanted to examine the safety and
ability of the vaccine to boost immune responses in an area of sub-
Saharan Africa where people are not exposed to malaria throughout the
year, but rather only in the wet season. The trial reported here was
carried out in northeast Mali, in which 40 adults received either the
FMP1/AS02A vaccine or a rabies vaccine for comparison, just at the start
of the malaria transmission season. The researchers primarily looked at
safety outcomes, collecting data on certain specific signs or symptoms
up to 8 d after immunization, other reported symptoms up to 31 d after
immunization, and any serious adverse events during a follow-up period
of 364 d after immunization. The researchers also examined antibody
levels in the participants’ blood against the MSP-1 protein.
What this trial shows: The researchers found that participants receiving
the FMP1/AS02A vaccine had more immediate symptoms at the injection
site (for example, pain or swelling) than the comparison group did. Other
general symptoms, both solicited and unsolicited, such as headache,
muscleaches,fever,andinfections,werealsomorecommoninthemalaria
vaccine group than in the group receiving the rabies vaccine. There were
twoseriousadverseeventsinthevaccinegroup,butthesewerenotjudged
toberelatedtothevaccination.Antibody levelsagainsttheMSP-1protein
increased in both study groups through the course of the rainy season
(when individuals would be likely exposed to bites from malaria-infected
mosquitoes)andsubsequentlyfellaftertheendofthemalariatransmission
season. However, participants receiving the vaccine had higher antibody
responses at all timepoints measured; the differences were statistically
significant at some timepoints, but not at others. Finally, the researchers
looked at antibody reactions against three different variants of the MSP-1
proteininserafromparticipantsreceivingthecandidatevaccineandfound
that the sera reacted similarly to all three variants.
Strengths and limitations: The study protocol followed established
procedures for phase I clinical trials of this type, which allows the data to
be compared across studies. Randomization procedures were appropri-
ate, and steps were taken to blind participants in the trial, as well as those
assessingoutcomes,totheinterventionparticipantsreceived.Alimitation
of this study, which can apply to other phase I studies in general, is that
small numbers of participants were recruited. Therefore, the trial was not
powered to detect statistically significant differences between participant
groups. It is also not clear whether the higher antibody levels seen in the
participants receiving the FMP1/AS02A vaccine would be biologically
significant (that is, act to prevent clinical malaria cases), a question that
would need to be addressed in further trials.
Contribution to the evidence: The safety results from this study are
similar to those from other trials and confirm that no safety concerns
have thus far been identified regarding the FMP1/AS02A vaccine, which
has now progressed to efficacy testing. This study was also conducted in
a population exposed to seasonal malaria, whereas previous trials had
been done among people exposed to malaria year-round. Finally, results
from the trial also suggest that this vaccine induces antibodies that
recognize genetically diverse forms of the vaccine antigen.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.transmission is strictly seasonal, with virtually undetectable
transmission at the height of the dry season in March, less
than one infected bite per person per month at the start and
end of the transmission season in June and December,
respectively, and peaks of up to 40–60 infected mosquito
bites per person per month in August or September [8]. P.
falciparum represents 97% of malaria infections, with 3% due
to P. malariae and rare infections with P. ovale. Despite the
seasonal transmission pattern, the malaria burden is heavy:
each year, children aged under 10 y old have an average of
two clinical malaria episodes every transmission season [8],
and severe malaria afﬂicts 1 in 50 children aged under 6 y old
[9]. Older children and adults are relatively protected against
malaria disease, but remain susceptible to malaria infection.
Participants
After obtaining community permission as described by Diallo
et al. [10], the trial was publicized by local radio broadcast.
Adults of both genders, aged 18–55 y, were invited to the
research clinic to be screened for eligibility. Participants were
included if they had resided in Bandiagara for at least 12 mo,
gave written informed consent, and, if female, declared their
intent not to become pregnant during the ﬁrst 4 mo of the
study. Exclusion criteria included current illness, previous
immunization with a rabies vaccine, recent use of immuno-
suppressants, receipt of blood products during the previous 6
mo, pregnancy or breast-feeding, alcohol or drug abuse, and
allergy to substances present in the vaccines.
Interventions
The FMP1 antigen consists of the 42-kDa carboxy-terminal
392 amino acids of MSP-1 based on the sequence of the 3D7
clone of P. falciparum and 17 non-MSP-1 amino acids
encoding a 6-histidine tag plus linking sequence fused to its
amino terminus. The antigen was expressed as a fusion
protein in E. coli with the 6-histidine tag to facilitate
puriﬁcation. The clinical grade antigen was manufactured
according to current Good Manufacturing Practices (cGMP)
at the Walter Reed Army Institute of Research Pilot
Bioproduction facility (Silver Spring, Maryland, United
States). The FMP1 protein met all purity, identity, and safety
standards set for product release. After puriﬁcation, less than
2 ng of host cell protein was detected per 50-lg dose. FMP1
protein was immunoreactive with several disulﬁde-dependent
conformational monoclonal antibodies (mAbs), including
growth inhibitory mAbs 12.10 and 12.8, implying correct
structural conformation [5].
The AS02A adjuvant is composed of an oil-in-water
emulsion and two immunostimulants, 3-deacylated mono-
phosphoryl lipid A and QS21, a saponin agent derived from
the soap bark tree, Quillaja saponaria [11,12]. AS02A was
manufactured by GlaxoSmithKline Biologicals (Rixensart,
Belgium) according to cGMP and provided in preﬁlled
syringes. A single dose of FMP1/AS02A contained 50 lgo f
antigen dissolved in 0.5 mL of AS02A adjuvant immediately
before injection.
The Imovax rabies vaccine (Aventis Pasteur, Swiftwater,
Pennsylvania, United States) is a sterile preparation of killed
rabies virus supplied in single-dose vials containing lyophi-
lized antigen to which 1 mL of sterile water is added as a
diluent before injection. Vaccines were administered by
intramuscular injection in the left deltoid muscle.
Forty adults were randomized in a 1:1 ratio to receive
either FMP1/AS02A or the control rabies vaccine. Vaccines
were given on a 0-, 1-, and 2-mo schedule. The ﬁrst
immunization was given in early July 2003, just as malaria
transmission began; the second dose was given at the end of
July, as transmission was increasing; and the third dose was
given in late August, near the peak of transmission intensity.
Study day 90 was in October, shortly after transmission crests
and when severe and uncomplicated malaria episodes peak;
study day 180 was at the end of the malaria season; and study
day 272 was in the middle of the dry season. The ﬁnal study
follow-up on day 364 coincided with the beginning of the
2004 malaria season. Interim safety reports were reviewed by
an independent safety monitoring committee before the
second and third immunizations.
Objectives
The primary objective was to evaluate the safety and
reactogenicity of the FMP1/AS02A malaria vaccine in
malaria-experienced Malian adults. Secondary objectives
were to evaluate the humoral immune response of the
vaccine in malaria-experienced Malian adults in a setting of
intense seasonal malaria transmission, to determine the
impact of natural infection on malaria vaccine-induced
antibody responses, and to measure antibody responses to
genetically diverse forms of MSP-142 and its subunits.
Outcomes
The primary outcome was safety, measured as (1) occurrence
of solicited symptoms during an 8-d follow-up period after
immunization (day of immunization and days 1, 2, 3, and 7
after immunization); (2) occurrence of unsolicited symptoms
during a 31-d follow-up period after immunization (day of
immunization and 30 subsequent days); (3) occurrence of
laboratory toxicities during the study period; and (4)
occurrence of serious adverse events during the study period.
Secondary outcomes were anti-MSP-1 antibody titers meas-
ured against recombinant MSP-142 3D7 and its subunits and
two genetically different parasite strains (P. falciparum FVO
and Camp/FUP), at baseline and at speciﬁed times during and
after immunization.
Assessment of safety and tolerability. Following each
immunization, participants were directly observed for 30
min, then evaluated at the study clinic 1, 2, 3, 7, and 14 d after
immunization and on study days 90, 180, 272, and 364.
Starting on day 180, monthly home visits were made to check
the health status of participants and to encourage them to
come to the research clinic if they felt ill. Study physicians
were available at all times throughout the 12-mo study to
assess and treat adverse events.
Clinical evaluations consisted of measurement of vital signs
and assessment for local injection site and general solicited
signs or symptoms. Local signs and solicited symptoms
included pain, swelling, erythema at the injection site, and
limitation of arm abduction at the shoulder. General signs
and solicited symptoms included fever (oral temperature
 37.5 8C), chills, nausea, headache, malaise, myalgia, and joint
pain. Any other signs or symptoms were considered to be
unsolicited, as were signs or symptoms that occurred more
than 7 d after immunization. Solicited symptoms were
considered to be related to the study vaccines. Unsolicited
signs and symptoms were recorded during the 30 d after each
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tored throughout the 12-mo study.
Blood was collected at screening, on immunization days, 14
d after each immunization, and on study days 90, 180, 272,
and 364 to determine complete blood count, alanine amino-
transferase (ALT), and serum creatinine.
Adverse events were graded by severity and judged for
relatedness to study vaccines. Mild adverse events were easily
tolerated, causing minimal discomfort and not interfering
with daily activities. Moderate adverse events were sufﬁciently
discomforting to interfere with normal activities. Severe
adverse events prevented normal daily activities. Swelling,
erythema, fever, and limitation of arm motion had speciﬁc
deﬁnitions not based on interference with daily activities.
Injection site swelling and erythema were graded based on
their widest dimension: mild, .0–20 mm; moderate, .20–50
mm; and severe, .50 mm. Fever was classiﬁed as severe if the
oral temperature was  39 8C , whereas severe limitation of
arm motion was classiﬁed as abduction limited to 308. For
laboratory tests, toxicity grading was adapted to normal
reference ranges determined for the local adult population.
Antibody responses to MSP-142. Antibody responses to
MSP-142 were measured by ELISA [6]. Brieﬂy, cGMP-puriﬁed
bulk MSP-142 [3] was used as plate antigen, and serial
dilutions of each sample, along with positive and negative
controls, were made to yield a linear range of dilutions that
could be analyzed with curve-ﬁtting software (SoftMax Pro
v4.1, Molecular Devices, Sunnyvale, California, United States)
to calculate the theoretical dilution that would give an optical
density of 1.0 in the endpoint assay; the reciprocals of these
calculated dilutions were reported as the sample titers. To
compare antibody responses to different alleles of MSP-142,
recombinant MSP-142 of the 3D7 and FVO alleles were
prepared as described previously [6,13]. Preparation of
recombinant MSP-142 of the Camp/FUP allele will be
described elsewhere.
Antibody responses to fragments of MSP-142. MSP-1 frag-
ment-speciﬁc antibody responses were assessed by a standard
ELISA [6]. Fragments of MSP-142 corresponding to MSP-119
(3D7 and FVO alleles) and the two epidermal growth factor
(EGF)-like domains that comprise MSP-119, EGF1 (3D7-Camp/
FUP [14] and FVO alleles) and EGF2 (3D7 and FVO-Camp/
FUP alleles), were expressed as glutathione S-transferase
fusion proteins and puriﬁed to homogeneity [13].
Sample Size
This phase I trial was not powered to detect differences
between groups. A sample size of 20 malaria vaccine
recipients was based on general acceptance of this size for
initial assessment of safety, tolerability, and immunogenicity
of investigational vaccines. Inclusion of a comparator vaccine
group of 20 permitted broad estimates of the incidence of
local and general side effects and immune responses to
natural infection.
Randomization
Randomization was done in blocks of four without stratiﬁ-
cation. Opaque, sealed randomization envelopes containing
sequential codes linked to vaccine assignment were prepared
by Statistics Collaborative (Washington, D. C., United States).
Codes were assigned in the order that participants arrived at
the clinic on the day of ﬁrst immunization.
Blinding
The only people at the study site with access to the
randomization codes during the study were two study
pharmacists, who had no contact with study participants
and did not reveal vaccine assignments to anyone else. Study
participants and investigators who assessed outcomes were
blinded to vaccine assignment. Vaccines were prepared in a
secure room communicating with the vaccine administration
room through a small window with a sliding door. Recon-
stituted FMP1/AS02A is off-white and Imovax is pink. To
reduce potential bias, syringes containing the vaccines were
wrapped with opaque tape to conceal their contents from
participants and vaccinators. Vaccines were administered by
physicians who did not participate in assessing outcomes.
Ethical Compliance
The protocol was approved by institutional review boards of
the University of Bamako Faculty of Medicine, the University
of Maryland, the United States Army Surgeon General, and
the National Institute of Allergy and Infectious Disease.
Separate written informed consent was obtained for screen-
ing and for enrollment. Consent of illiterate participants was
documented by their thumbprints and by signatures of
independent witnesses. Permission to conduct the study was
granted by the Republic of Mali Ministry of Health, and the
trial was monitored by the United States Army Medical
Materiel Development Activity and the World Health Organ-
ization.
Statistical Methods
Adverse event rates were analyzed using SAS version 8.2 (SAS
Institute, Cary, North Carolina, United States). Fisher’s exact
test was used to compare rates between vaccine groups.
Conﬁdence intervals (CIs) for geometric mean MSP-142
antibody titers were estimated by using log10-transformed
values, calculating the 95% CI based on the normal
distribution, and then converting the limits to the original
scale for presentation. All tests were two-sided, and no
correction of p-values was made for additional analyses. MSP-
Figure 1. Trial Profile
doi:10.1371/journal.pctr.0010034.g001
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longitudinally and are reported as the median slope of the
regression lines for responses for the malaria vaccine and
control groups. Comparisons between groups were made
using Mann–Whitney tests or Student’s t test of log10-
transformed antibody titers.
RESULTS
Participant Flow and Baseline Data
Of 108 screened adults, 40 were deemed eligible and enrolled
in July 2003 (Figure 1). The main reasons for exclusion were
concurrent illnesses and intent to travel during the trial. The
two vaccine groups did not differ signiﬁcantly at enrollment
with regard to sex, age, or laboratory parameters (Table 1).
Seven participants were female. The mean age was 39 y. All
participants received all three immunizations according to
the 0-, 1-, and 2-mo schedule. All participants completed all
scheduled visits and were included in the analysis.
Safety and Reactogenicity
Local solicited adverse events. After each immunization, the
proportion of participants who had at least one local
injection site reaction during the 8-d post-immunization
periods was not signiﬁcantly different between vaccine
groups. Pain and swelling at the injection site were the most
common local reactions for both groups and tended to be
more common in the FMP1/AS02A group and after the ﬁrst
immunization (Table 2).
After the ﬁrst immunization, nine recipients of FMP1/
AS02A and none of the rabies vaccine recipients had at least
one instance of severe injection site swelling (p ¼ 0.001). No
other severe reactions were observed. Severe local swelling
was less common after the second and third immunizations
and was similar in frequency between groups. Severe
injection site swelling occurred in 13 FMP1/AS02A recipients
across all immunizations (in nine, six, and three participants
after the ﬁrst, second, and third immunization, respectively)
and in eight rabies vaccine recipients across all immuniza-
tions (in zero, ﬁve, and three participants after the ﬁrst,
second, and third immunizations, respectively) (Table 2). The
swelling was typically unnoticed by the participant and
detected only on physical examination and did not interfere
with normal daily activities. No other severe local adverse
events occurred. Six episodes of arm motion limitation were
reported among FMP1/AS02A recipients: one mild episode
after the ﬁrst immunization; and two moderate and one mild
episode after the second immunization. All local solicited
symptoms resolved without sequelae during the 8-d post-
immunization periods.
General solicited adverse events. The FMP1/AS02A group
had a higher proportion of participants who had at least one
general solicited sign or symptom during the 8-d post-
immunization periods (19/20 FMP1/AS02A recipients versus
12/20 rabies vaccine recipients; p ¼ 0.02). Headache was the
most common general adverse event in FMP1/AS02A recip-
ients after each immunization, followed by myalgia and
malaise (Table 2). All general solicited adverse events were of
mild or moderate intensity and ended during the 8-d follow-
up period.
Unsolicited adverse events. The most common nonserious,
unsolicited adverse events were subjective fever, infections,
and rhinitis. During the three 31-d post-immunization
periods, 13 participants in the FMP1/AS02A group and seven
in the control group had subjective fever at least once. One or
.......................................................................................
Table 1. Baseline Characteristics of FMP1/AS02A Malaria





Mean age in years (SD) 40.3 (8.0) 38.5 (10.1)
Number of females 5 2
Mean WBC 3 10
3/lL (SD) 5.7 (1.32) 5.9 (1.65)
Mean hemoglobin (g/dL) (SD) 14.5 (1.46) 14.8 (1.54)
Mean platelets 3 10
3/lL (SD) 253 (95.0) 228 (62.5)
Mean lymphocytes 3 10
3/lL (SD) 2.1 (0.4) 2.1 (0.73)
Mean creatinine (mM/L) (SD) 75.6 (14.69) 78.9 (11.24)
Mean ALT (U/L) (SD) 16.1 (4.92) 16.5 (5.15)
GMT anti-MSP-1 antibody
titer (95% CI)
5,858 (2,650–12,950) 3,282 (1,423–7,568)
GMT, geometric mean titer; SD, standard deviation; WBC, white blood cell count.
doi:10.1371/journal.pctr.0010034.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 2. Signs and Solicited Symptoms during the 8-d Follow-Up Periods after Each Immunization













Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe
Local Pain (%) 11 (55) 0 8 (40) 0 4 (20) 0 3 (15) 0 2 (10) 0 1 (5) 0
Limited arm motion (%) 2 (10) 0 3 (15) 0 1 (5) 0 0 0 0 0 0 0
Swelling (%) 10 (50) 9 (45) 7 (35) 6 (30) 8 (40) 3 (15) 1 (5) 0 6 (30) 5 (25) 8 (40) 3 (15)
Erythema (%) 0 0 0 0 0 0 0 0 0 0 0 0
General Fever (%) 5 (25) 0 1 (5) 0 1 (5) 0 3 (15) 0 0 0 0 0
Headache (%) 6 (30) 0 9 (45) 0 6 (30) 0 2 (10) 0 5 (25) 0 3 (15) 0
Joint pain (%) 2 (10) 0 5 (25) 0 0 0 0 0 0 0 1 (5) 0
Myalgia (%) 2 (10) 0 6 (30) 0 3 (15) 0 0 0 0 0 0 0
Malaise (%) 2 (10) 0 3 (15) 0 3 (15) 0 2 (10) 0 4 (20) 0 1 (5) 0
Nausea (%) 2 (10) 0 1 (5) 0 1 (5) 0 1 (5) 0 1 (5) 0 1 (5) 0
Chills (%) 3 (15) 0 2 (10) 0 2 (10) 0 1 (5) 0 2 (10) 0 1 (5) 0
doi:10.1371/journal.pctr.0010034.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Malaria Vaccine in Malimore genitourinary and lower respiratory infections oc-
curred in nine FMP1/AS02A recipients and in ﬁve rabies
vaccine recipients in the same periods. Rhinitis was reported
by eight participants in the FMP1/AS02A group and by six in
the rabies group. Only one severe unsolicited adverse event, a
urinary tract infection in a female FMP1/AS02A recipient,
occurred during the 31-d post-immunization periods. These
unsolicited events were not temporally associated with
immunization and were not considered to be related to
vaccination. The incidence of unsolicited adverse events was
not signiﬁcantly different between the two study groups.
Serious adverse events. Two serious adverse events
occurred during the study, both in the FMP1/AS02A group.
One participant developed sinusitis requiring hospitalization
between the second and third immunizations, and the other
had a tubal ectopic pregnancy a month after her third
immunization. Both participants recovered fully, and both
events were judged to be unrelated to immunization.
Laboratory safety tests. Mildly elevated serum creatinine
levels were detected in seven participants (three in the FMP1/
AS02A group and four in the control group). These were not
associated with other clinical abnormalities or illness and
resolved without intervention. Two participants in the
control group had elevated ALT levels. One was a moderate
elevation to 131 U/L detected during an acute malaria
episode on day 272 that returned to normal by day 364.
The second was a severe elevation to 359 U/L unaccompanied
by symptoms or signs of hepatitis or other illness that was
detected on day 74 and resolved by day 272. Serological tests
for hepatitis A, B, and C were negative. The participant had
been treated with erythromycin for a respiratory infection
and was given a diagnosis of drug-induced hepatitis.
Hemoglobin levels remained within or slightly above the
normal range for all participants throughout the study (11.7–
17.3 g/dL for males; 10.0–14.4 g/dL for females). Mild
abnormalities in white blood cell and platelet counts were
infrequent and balanced by group.
Immunogenicity
In the rabies vaccine group, anti-MSP-142 antibodies rose
over the course of the malaria season, increasing more than
2-fold by day 60 and peaking at nearly 3-fold above baseline
responses on day 180 as the malaria season ended (Figure 2;
Table 3). Titers then decreased throughout the dry season
and returned to near baseline levels by the start of the
subsequent rainy season. In the FMP1/AS02A vaccine recip-
ients, although the shape of the curve is similar, the
magnitude of the response was signiﬁcantly greater, with a
6.5-fold increase between day 0 and day 90, 30 d after the
third immunization. At day 90, the geometric mean titers
were 37,923 in the FMP1/AS02A recipients and 6,892 in the
comparator group (p , 0.001), and at day 180, they were
29,150 and 9,089 (p ¼0.016). By the ﬁnal follow-up timepoint
1 y after immunization, although titers had waned in both
groups, they remained signiﬁcantly higher in the FMP1/
AS02A group (14,693 compared to 5,015 in the control group;
p ¼ 0.032).
Individual responses to the vaccine varied. Of the 20
participants who received FMP1/AS02A, six developed very
high antibody titers, with an 8-fold or greater rise in day-90
antibody titers compared to baseline; six had a 4- to 7-fold
rise; four had a 2- to 3-fold rise; and four had a ,2-fold rise.
Much of this individual variation can be explained by the
variation in background immunity at the start of the malaria
transmission season: the baseline geometric mean MSP-142
titer was ,3,000 in the six participants with an 8-fold or
greater rise in titer, but .20,000 in those with a ,2-fold rise.
Fragment- and Allele-Specific Anti-MSP-142 Antibody
Responses
Timepoints for measurement of the rates of acquisition of
MSP1 fragment-speciﬁc antibodies in this adult population
with signiﬁcant baseline antibodies were chosen from the
observed maxima for antibody to the entire MSP-142, i.e., days
74 and 90. Sera collected on study day 0 were analyzed to
provide paired baseline data. Responses were measured by
ELISA against three alleles of MSP-142 (3D7, Camp/FUP, and
Figure 2. Anti-MSP-142 Antibody Titers
Geometric mean antibody titers to homologous recombinant MSP-142 for
FMP1/AS02A vaccine (solid line) and control rabies vaccine (dotted line)
recipients. Times of each of three immunizations and the start and end of the
malaria transmission season are indicated by arrows. Bars represent 95% CI.
doi:10.1371/journal.pctr.0010034.g002
.......................................................................................





GMT 95% CI GMT 95% CI
Pre-immunization 5,858 2,650–12,950 3,282 1,423–7,568
Day 14 7,627 3,561–16,336 3,089 1,332–7,161
Day 30 8,007 3,809–16,831 3,485 1,391–8,728
Day 44
a 20,044 12,994–30,919 4,036 1,796–9,071
Day 60
a 26,321 19,611–35,326 6,915 3,148–15,190
Day 74
a 35,194 25,254–47,194 7,051 3,477–14,300
Day 90
a 37,923 26,788–53,686 6,892 3,645–13,029
Day 180
a 29,150 18,301–46,432 9,089 3,817–21,645
Day 272
a 19,518 11,181–34,072 6,367 2,743–14,779
Day 364
a 14,693 8,216–26,276 5,015 2,194–11,462
aSignificantly different at p , 0.05.
GMT, geometric mean titer.
doi:10.1371/journal.pctr.0010034.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.plosclinicaltrials.org November | 2006 | e34 0006
Malaria Vaccine in MaliFVO) and subunit fragments of MSP-142 from both 3D7 and
FVO (MSP-142,M S P - 1 19, EGF-1, and EGF-2). Antibody
responses induced by FMP1/AS02A against the three alleles
did not differ signiﬁcantly (Figure 3), although there was a
tendency toward greater recognition of the 3D7 and Camp/
FUP alleles compared to the FVO allele (p ¼ 0.08 and 0.064,
respectively). For all comparisons, slopes for anti-MSP-142
and subunit antibodies were signiﬁcantly higher in the FMP1/
AS02A group than in the rabies control group (Table 4).
DISCUSSION
Interpretation
The P. falciparum blood-stage vaccine FMP1/AS02A was safe,
well tolerated, and highly immunogenic against diverse
parasite clones in adults with lifelong exposure to intense
seasonal malaria transmission in Bandiagara, Mali.
As in two previous phase I trials of FMP1/AS02A [6,7], the
vaccine had acceptable tolerability, with most reactogenicity
occurring after the ﬁrst of the three immunizations and
decreasing reactogenicity after the second and third immu-
nizations. In general, we observed more solicited adverse
events in the FMP1/AS02A group when compared to the
rabies group, with the most common reactions being short-
lived swelling and mild pain at the injection site. Although
swelling was often classiﬁed as severe based on the size of the
reaction, these episodes were well tolerated and were usually
unnoticed by participants. No participants were withdrawn
from the study because of adverse events. No serious adverse
event related to the vaccine was observed. No clinically
signiﬁcant laboratory abnormality related to the vaccine
occurred. Hemoglobin levels remained at or above normal
ranges for all participants during the study period.
Immunization with FMP1/AS02A led to increased antibody
titers against MSP-142, which peaked with a 6.5-fold rise over
baseline 1 mo after the third immunization. A boosting effect
was seen after each of three immunizations, in contrast to a
trial of this vaccine in malaria-naı ¨ve North Americans [6], in
which the third immunization did not lead to a signiﬁcant
additional rise in titer.
Generalizability
While cellular immune responses, antibody avidity assays,
growth inhibition assays, and other potential alternative
surrogate markers may eventually prove more predictive of
clinical protection than MSP-142 antibody titers, the validity
of these assays as endpoints for clinical trials will need to be
demonstrated in appropriate target populations (e.g., infants
and children in malaria-endemic areas) in which protective
efﬁcacy is demonstrated. For this small phase I trial in
malaria-experienced adults, we chose to use MSP-142 anti-
body titers as the immunogenicity endpoint to inform clinical
development decisions.
Overall Evidence
Immunizing at the start of the of the malaria transmission
season permitted observation of the effect of natural
boosting on MSP-142 antibody titers in the control group,
which rose nearly 3-fold over the malaria season. The
difference in MSP-142 antibody levels between the FMP1/
AS02A and rabies vaccine groups was much greater in this
trial than in a virtually identical trial conducted in an area of
intense year-round malaria transmission in Kenya [7]. The
same reference laboratory measured antibody titers in both
trials using the same methods, ruling out methodological
reasons for the different immunogenicity results. Most of this
difference can be attributed to the lower baseline antibody
levels at the beginning of the malaria transmission season in
Mali: in the FMP1/AS02A vaccine group, antibody titers rose
from ,6,000 to a peak of nearly 38,000 in Mali, compared to
an increase from 17,000 to 46,000 in Kenya [7]. This
conclusion is supported by the observation that the rates of
Figure 3. Allele-Specific Anti-MSP-142 Antibody Titers
Linear regression of point-wise geometric mean titers against the three allelic
forms of MSP-142 measured at study days 0, 74, and 90. Bars represent 95% CI.
doi:10.1371/journal.pctr.0010034.g003
.......................................................................................................................................................................................
Table 4. Median Slope of the Regression Line for Day 0, 74, and 90 Antibody Responses to 3D7 (Homologous to the FMP1 Vaccine
Antigen) and FVO Allelic Types of MSP-1 42-kDa, 33-kDa, 19-kDa, EGF-1, and EGF-2 Subunits
Antigen 3D7 Allele FVO Allele Camp/FUP Allele
FMP1 (n ¼ 20) Rabies (n ¼ 20) p FMP1 (n ¼ 20) Rabies (n ¼ 20) p FMP1 (n ¼ 20) Rabies (n ¼ 20) p
Slope Slope Slope Slope Slope Slope
MSP-142 112 14 ,0.001 50 8 ,0.01 161 14 ,0.001
MSP-133 21 6 0.004 ND ND ND 21 6 0.004
MSP-119 52 9 ,0.001 48 5 ,0.01 ND ND ND
EGF-1 21 1 ,0.001 15 0 ,0.01 21 1 ,0.001
EGF-2 1 0 0.005 1 0 0.02 1 0 0.02
ND, not done or recombinant subunit is not available.
doi:10.1371/journal.pctr.0010034.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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increase in vaccine-induced antibody responses to the 3D7
alleles of MSP-142 and MSP-119, as measured by the slopes of
the regression lines ﬁtted using data from day 0, 74, and 90,
were not different between the two study sites (data not
shown).
The vaccine induced responses against all alleles tested:
3D7 (homologous to the vaccine antigen), Camp/FUP (differ-
ent in three amino acids in the second EFG-like domain), and
FVO (different in four amino acids in MSP-119, and the most
divergent in MSP-133). Longitudinal antibody responses
showed a tendency toward stronger reactivity against the
3D7 and Camp/FUP alleles than against the FVO allele, which
is consistent with the greater degree of homology between
3D7 and Camp/FUP than between 3D7 and FVO. Whether
these in vitro allele-speciﬁc analyses predict in vivo efﬁcacy
against diverse parasites is not yet known.
The dramatically different immune responses to FMP1/
AS02A seen in Mali and Kenya highlight the need to assess
malaria vaccines in different transmission settings early in
their development. Conceivably, high background immunity
could obscure vaccine-induced immunity to the extent that a
potentially efﬁcacious vaccine tested only in high trans-
mission settings would be prematurely abandoned. Settings
with seasonal transmission offer the advantages of relatively
lower background immunity yet high clinical attack rates [8]
that make them particularly suitable for phase I and II
malaria vaccine trials.
In a recent trial in Mozambique, the pre-erythrocytic
malaria vaccine RTS,S/AS02A provided signiﬁcant, sustained
protection against both severe and uncomplicated malaria
[15,16]. Presently, a randomized, placebo-controlled efﬁcacy
trial of FMP1/AS02A is underway in 400 Kenyan children 1–4
y of age. If clinical protection is demonstrated, FMP1/AS02A
may have the potential for development as a vaccine and/or
to enhance the protection conferred by RTS,S in a multi-
antigen, multistage malaria vaccine [17].
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0010034.sd001 (49 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0010034.sd002 (376 KB PDF).
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